Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment
22/10/2018 – Final results will be available in 2019.
22/10/2018 – Final results will be available in 2019.
08/10/2018 – Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib’s mode of action in ALS.
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.